SGRY
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Supports a bullish reading. Current ratio 1.87 · operating margin 12%
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 21 250 titres (~304 512,50 $ US)
- Insiders
- DeLuca Teresa
- Total bought
-
$304,512
Avg buy (VWAP, 90d window) $14.35 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-08-18
- Last synced
-
2026-08-25 17:08:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-18 | DeLuca Teresa | Buy | 10,000 | $14.35 | $143,500 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-08-21
SGRY posted a genuine earnings catalyst — Q2 2026 beat on revenue and EBITDA with full-year guidance reaffirmed, a post-earnings gap-up, and insider buying by Teresa DeLuca (Aug 18), all supporting a moderately…
The first sentence of the analysis written for SGRY on 2026-08-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 23.1% | 23.9% | 23.6% | 22.6% | 22.1% | |
| Ebit Margin | 11.8% | 11.2% | 12.0% | 13.6% | 13.6% | |
| Ebitda Margin | 17.1% | 16.1% | 16.3% | 18.1% | 18.0% | |
| Operating Profit Margin | 11.8% | 11.2% | 12.0% | 13.6% | 13.6% | |
| Pretax Profit Margin | 3.5% | 4.7% | 4.9% | 4.3% | 3.6% | |
| Continuous Operations Profit Margin | 3.0% | 0.4% | 4.9% | 3.4% | 3.2% | |
| Net Profit Margin | -2.4% | -5.4% | -0.4% | -2.2% | -3.2% | |
| Bottom Line Profit Margin | -2.4% | -5.4% | -0.4% | -2.2% | -3.6% | |
| Current Ratio | 1.870 | 1.793 | 1.711 | 1.867 | 1.762 | |
| Quick Ratio | 1.713 | 1.651 | 1.567 | 1.722 | 1.649 | |
| Solvency Ratio | 0.021 | -0.004 | 0.030 | 0.018 | 0.007 | |
| Cash Ratio | 0.390 | 0.432 | 0.375 | 0.573 | 0.726 | |
| Price To Earnings Ratio | -25.328 | -15.917 | -337.804 | -47.220 | -47.687 | |
| Price To Earnings Growth Ratio | 0.468 | -0.012 | 4.024 | 0.998 | 0.735 | |
| Forward Price To Earnings Growth Ratio | 0.468 | -0.012 | 4.024 | 0.998 | 0.735 | |
| Price To Earnings Diluted Ratio | -25.328 | -15.917 | -337.804 | -47.220 | -47.687 | |
| Price To Earnings Diluted Growth Ratio | 0.468 | -0.012 | 4.024 | 0.998 | 0.735 | |
| Price To Book Ratio | 1.147 | 1.492 | 2.022 | 1.282 | 3.552 | |
| Price To Sales Ratio | 0.594 | 0.857 | 1.465 | 1.009 | 1.738 | |
| Price To Free Cash Flow Ratio | 10.048 | 12.732 | 19.602 | 32.759 | 131.130 | |
| Price To Operating Cash Flow Ratio | 7.165 | 8.897 | 13.677 | 16.132 | 44.412 | |
| Debt To Assets Ratio | 0.488 | 0.469 | 0.445 | 0.438 | 0.539 | |
| Debt To Equity Ratio | 2.350 | 2.069 | 1.541 | 1.466 | 3.025 | |
| Debt To Capital Ratio | 0.701 | 0.674 | 0.606 | 0.595 | 0.752 | |
| Long Term Debt To Capital Ratio | 0.612 | 0.646 | 0.576 | 0.562 | 0.726 | |
| Financial Leverage Ratio | 4.812 | 4.409 | 3.460 | 3.344 | 5.618 | |
| Working Capital Turnover Ratio | 6.423 | 7.184 | 6.862 | 6.068 | 6.805 | |
| Operating Cash Flow Ratio | 0.446 | 0.481 | 0.562 | 0.322 | 0.162 | |
| Operating Cash Flow Sales Ratio | 0.083 | 0.096 | 0.107 | 0.063 | 0.039 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.713 | 0.699 | 0.698 | 0.492 | 0.339 | |
| Debt Service Coverage Ratio | 1.472 | 1.210 | 1.676 | 1.467 | 1.388 | |
| Interest Coverage Ratio | 1.429 | 1.729 | 1.699 | 1.470 | 1.367 | |
| Short Term Operating Cash Flow Coverage Ratio | 2.762 | 2.960 | 4.008 | 2.529 | 1.442 | |
| Operating Cash Flow Coverage Ratio | 0.068 | 0.081 | 0.096 | 0.054 | 0.026 | |
| Capital Expenditure Coverage Ratio | 3.485 | 3.320 | 3.309 | 1.970 | 1.512 | |
| Dividend Paid And Capex Coverage Ratio | 3.485 | 3.320 | 3.309 | 1.970 | 1.389 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | -0.072 | |
| Enterprise Value Multiple | 10.168 | 12.174 | 15.432 | 11.323 | 16.890 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 23.1% | ▼-0.8% | ▲0.0% |
| Ebit Margin | 11.8% | ▲0.6% | ▼-0.7% |
| Ebitda Margin | 17.1% | ▲1.0% | ▼-0.0% |
| Operating Profit Margin | 11.8% | ▲0.6% | ▼-0.7% |
| Pretax Profit Margin | 3.5% | ▼-1.2% | ▼-0.7% |
| Continuous Operations Profit Margin | 3.0% | ▲2.6% | 0.0% |
| Net Profit Margin | -2.4% | ▲3.0% | ▲0.4% |
| Bottom Line Profit Margin | -2.4% | ▲3.0% | ▲0.4% |
| Current Ratio | 1.869 | ▲0.077 | ▲0.069 |
| Quick Ratio | 1.713 | ▲0.061 | ▲0.052 |
| Solvency Ratio | 0.021 | ▲0.024 | ▲0.006 |
| Cash Ratio | 0.390 | ▼-0.042 | ▼-0.109 |
| Price To Earnings Ratio | -25.328 | ▼-9.411 | ▲69.463 |
| Price To Earnings Growth Ratio | 0.468 | ▲0.480 | ▼-0.775 |
| Forward Price To Earnings Growth Ratio | 0.468 | ▲0.480 | ▼-0.775 |
| Price To Earnings Diluted Ratio | -25.328 | ▼-9.411 | ▲69.463 |
| Price To Earnings Diluted Growth Ratio | 0.468 | ▲0.480 | ▼-0.775 |
| Price To Book Ratio | 1.147 | ▼-0.344 | ▼-0.752 |
| Price To Sales Ratio | 0.594 | ▼-0.263 | ▼-0.539 |
| Price To Free Cash Flow Ratio | 10.048 | ▼-2.684 | ▼-31.206 |
| Price To Operating Cash Flow Ratio | 7.165 | ▼-1.732 | ▼-10.892 |
| Debt To Assets Ratio | 0.488 | ▲0.019 | ▲0.012 |
| Debt To Equity Ratio | 2.350 | ▲0.280 | ▲0.260 |
| Debt To Capital Ratio | 0.702 | ▲0.027 | ▲0.036 |
| Long Term Debt To Capital Ratio | 0.612 | ▼-0.034 | ▼-0.012 |
| Financial Leverage Ratio | 4.812 | ▲0.403 | ▲0.483 |
| Working Capital Turnover Ratio | 6.423 | ▼-0.761 | ▼-0.245 |
| Operating Cash Flow Ratio | 0.446 | ▼-0.035 | ▲0.051 |
| Operating Cash Flow Sales Ratio | 0.083 | ▼-0.013 | ▲0.005 |
| Free Cash Flow Operating Cash Flow Ratio | 0.713 | ▲0.014 | ▲0.125 |
| Debt Service Coverage Ratio | 1.472 | ▲0.262 | ▲0.029 |
| Interest Coverage Ratio | 1.429 | ▼-0.300 | ▼-0.110 |
| Short Term Operating Cash Flow Coverage Ratio | 2.762 | ▼-0.197 | ▲0.022 |
| Operating Cash Flow Coverage Ratio | 0.068 | ▼-0.013 | ▲0.003 |
| Capital Expenditure Coverage Ratio | 3.485 | ▲0.166 | ▲0.766 |
| Dividend Paid And Capex Coverage Ratio | 3.485 | ▲0.166 | ▲0.791 |
| Dividend Payout Ratio | 0.000 | 0.000 | ▲0.014 |
| Enterprise Value Multiple | 10.168 | ▼-2.005 | ▼-3.029 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.97B | $2.67B | $4.02B | $2.56B | $3.87B | |
| Enterprise value | $5.75B | $6.10B | $6.88B | $5.21B | $6.77B | |
| EV / Sales | 1.74x | 1.96x | 2.51x | 2.05x | 3.04x | |
| EV / Op. cash flow | 20.96x | 20.34x | 23.43x | 32.80x | 77.76x | |
| EV / Free cash flow | 29.40x | 29.11x | 33.58x | 66.61x | 229.59x | |
| EV / EBITDA | 10.17x | 12.17x | 15.43x | 11.32x | 16.89x | |
| Net debt / EBITDA | 6.69x | 6.85x | 6.42x | 5.75x | 7.24x | |
| Current ratio | 1.87x | 1.79x | 1.71x | 1.87x | 1.76x | |
| Income quality | 2.77x | 24.01x | 2.17x | 1.82x | 1.23x | |
| Graham net-net | -$31 | -$28 | -$23 | -$30 | -$42 | |
| Tax burden | -66.6% | -114.3% | -8.8% | -49.5% | -87.3% | |
| Interest burden | 30.0% | 42.2% | 41.2% | 32.0% | 26.9% | |
| Working capital | $535.2M | $495.0M | $372.0M | $427.6M | $409.3M | |
| Invested capital | $7.21B | $6.99B | $5.98B | $5.76B | $5.32B | |
| Return on assets | -0.9% | -2.1% | -0.2% | -0.8% | -1.2% | |
| Operating ROA | 4.8% | 4.7% | 4.8% | 5.4% | 5.2% | |
| Return on tangible assets | -2.6% | -6.1% | -0.5% | -2.2% | -3.3% | |
| Return on equity | -4.5% | -9.4% | -0.6% | -2.7% | -6.5% | |
| Return on invested capital | 4.2% | 0.4% | 5.1% | 4.3% | 4.6% | |
| Return on capital employed | 5.1% | 4.8% | 5.2% | 5.6% | 5.4% | |
| Earnings yield | -4.0% | -6.3% | -0.3% | -2.1% | -1.8% | |
| Free cash flow yield | 10.0% | 7.9% | 5.1% | 3.1% | 0.8% | |
| Capex / Op. cash flow | 28.7% | 30.1% | 30.2% | 50.8% | 66.1% | |
| Capex / Depreciation | 44.7% | 59.2% | 75.2% | 70.2% | 58.3% | |
| Capex / Sales | 2.4% | 2.9% | 3.2% | 3.2% | 2.6% | |
| SG&A / Sales | 15.8% | 4.5% | 4.4% | 4.0% | 4.7% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.4% | 1.1% | 0.6% | 0.7% | 0.8% | |
| Intangibles / Total assets | 63.5% | 64.8% | 63.7% | 62.5% | 64.7% | |
| Days sales outstanding | 66d | 68d | 66d | 66d | 71d | |
| Days payables outstanding | 30d | 32d | 30d | 28d | 26d | |
| Operating cycle | 80d | 81d | 79d | 79d | 83d | |
| Cash conversion cycle | 50d | 49d | 49d | 51d | 57d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-26.4%EV / Sales ▼-11.3%EV / EBITDA ▼-16.5%EV / Op. cash flow ▲+0.624Earnings yield ▲+0.023
Profitability
Return on equity ▲+0.048Return on assets ▲+0.012Return on invested capital ▲+0.038Return on capital employed ▲+0.003Operating ROA ▲+0.001Income quality ▼-21.234Tax burden ▲+0.476
Efficiency
Days sales outstanding ▼-1.439Days payables outstanding ▼-2.212Operating cycle ▼-1.200Cash conversion cycle ▲+1.013Capex / Sales ▼-0.005R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.077Net debt / EBITDA ▼-0.156Working capital ▲+40200000.000Invested capital ▲+220700000.000Intangibles / Total assets ▼-0.013
Change over 5 years
Valuation
Market cap ▼-49.2%EV / Sales ▼-42.9%EV / EBITDA ▼-39.8%EV / Op. cash flow ▼-56.797Earnings yield ▼-0.021
Profitability
Return on equity ▲+0.020Return on assets ▲+0.002Return on invested capital ▼-0.004Return on capital employed ▼-0.003Operating ROA ▼-0.004Income quality ▲+1.542Tax burden ▲+0.207
Efficiency
Days sales outstanding ▼-4.137Days payables outstanding ▲+3.651Operating cycle ▼-3.139Cash conversion cycle ▼-6.791Capex / Sales ▼-0.002R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.107Net debt / EBITDA ▼-0.550Working capital ▲+125900000.000Invested capital ▲+1894800000.000Intangibles / Total assets ▼-0.011
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-08-11 Likely ETF & Stock Winners From July Jobs Report Weak July jobs data raises hopes for Fed easing, putting health care and select retail ETFs and stocks in focus.
- 2026-08-11 Surgery Partners (NASDAQ:SGRY) Shares Gap Up Following Strong Earnings Surgery Partners, Inc. (NASDAQ: SGRY - Get Free Report) shares gapped up prior to trading on Monday following a better than expected earnings announcement. The stock had previously closed at $15.53, but opened at $16.46. Surgery Partners shares last traded at $15.9050, with a volume of 173,693 shares. The company reported $0.10 earnings per share (EPS)
- 2026-08-10 Surgery Partners, Inc. (SGRY) Q2 2026 Earnings Call Transcript Surgery Partners, Inc. (SGRY) Q2 2026 Earnings Call Transcript
- 2026-08-10 Surgery Partners Q2 Earnings Call Highlights Surgery Partners NASDAQ: SGRY reported second-quarter 2026 revenue and adjusted EBITDA above its internal expectations, while reaffirming its full-year outlook ahead of the anticipated sale of its Idaho Falls market operations to Intermountain Health.
- 2026-08-10 Surgery Partners (SGRY) Q2 Earnings and Revenues Beat Estimates Surgery Partners (SGRY) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.17 per share a year ago.
- 2026-07-31 Is Surgery Partners Inc (SGRY) a Bargain After 3.1% Drop? GF Value Says Undervalued On July 31, 2026, Surgery Partners Inc (SGRY) shares fell 3.1% to a current price of $15.38. This decline comes amid a 52-week trading range of $11.41 to $24.10
- 2026-07-30 Strength Seen in Surgery Partners (SGRY): Can Its 5.3% Jump Turn into More Strength? Surgery Partners (SGRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- 2026-07-24 Surgery Partners Monetizes Idaho Assets As It Chases Faster Growth Surgery Partners, Inc. (NASDAQ:SGRY) stock is trading higher on Friday as the company announced a significant transaction involving the sale of its ownership interests in Idaho Falls facilities to Intermountain Health.
- 2026-07-24 Surgery Partners Announces Entry Into Agreement to Sell Ownership Interests in Idaho Falls Facilities to Intermountain Health; Reaffirms Guidance, Excluding Impact of Transaction BRENTWOOD, Tenn., July 24, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced it, along with its existing partner Intermountain Health, has placed into escrow signature pages to definitive agreements, pursuant to which Surgery Partners would sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health.
- 2026-07-08 Fast-paced Momentum Stock Surgery Partners (SGRY) Is Still Trading at a Bargain Surgery Partners (SGRY) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our ''Fast-Paced Momentum at a Bargain'' screen.